The nasal vaccine, tested on animals since 2021, may offer a new tool in fighting COVID-19 with a non-invasive, ...

While mRNA vaccines represent a transformative platform for infectious disease control, their efficacy in antigen-presenting cells (APCs) remains vulnerable to endogenous regulatory networks, ...

The FDA has discussed with vaccine-maker Novavax the need for an additional trial of its COVID-19 vaccine as a post-approval commitment ...